Research groups

Translational Pediatric Sarcoma Research

Translational Pediatric Sarcoma Research

The mission of the division of "Translational Pediatric Sarcomas Research", which corresponds to the DKFZ division of the same name, is to improve treatment options for children and adolescents affected by sarcomas. We aim at uncovering disease mechanisms that can be used diagnostically and therapeutically to improve the long-term chances of recovery of our young patients. The focus lies on new methods that are essential for correct diagnosis and the choice of the best possible therapy. We also investigate less aggressive therapies and new approaches to overcome drug resistance of tumors. In this regard, one special objective is to decipher the interactions between acquired mutations and innate natural variants of the genome, which can play a decisive role in the development and progression of cancer, particularly in Ewing sarcoma.

We aim at developing novel therapeutic strategies based on new insights into the molecular mechanisms of disease following two major lines of research (see research areas). Our investigations start with the analysis of the patients’ tumors in situ, followed by studying patient-derived cell lines using a wide variety of in silico, in vitro, and in vivo techniques.

The division is supported by the Barbara und Wilfried Mohr Stiftung.

Translational spectrum of methods

Histology, omics‘-analyses, preclinical models, correlation with clinical data

Research areas

Dominant oncogenes often hijack or interfere with developmental pathways thereby conferring a considerable growth advantage to tumor cells. We are interested in the mechanisms through which oncogenes arrest sarcoma cells in a lineage-specific, early-committed but yet largely undifferentiated state via deregulation of key developmental pathways, and how they cooperate with them to promote tumorigenesis and cancer progression.

Primary and/or secondary resistance to conventional chemotherapeutic drugs is a frequent event in pediatric sarcoma. Chemo-resistance is a highly specific process in which tumors become resistant to certain drugs while maintaining (limited) susceptibility toward others. Underlying to this resistance is considerable plasticity due to intra-tumor heterogeneity, which enables the adaptation to therapeutic stress on the clonal and sub-clonal level. We strive for illuminating the genetic basis and biological mechanisms of tumor-heterogeneity and aim at identifying novel biomarkers for individualized risk-stratification, prediction of treatment response, and to indicate which targeted therapeutics may help overcoming resistance to conventional (chemo)therapeutics.


Research Teams

The team Translational Genomics (T. Grünewald) systematically established multi-dimensional omics-datasets of a large number of pediatric sarcomas and correlates identified molecular alterations with clinical data to identify novel driver mutations, druggable targets and prognostic/predictive biomarkers, and to create resources for hypothesis generation and functional validation.

The team Mechanisms of Cancer Progression (F. Cidre-Aranaz) aims at deconvoluting the multilayered process underlying cancer progression and metastasis. We employ systems biology approaches combining in vitro and in vivo functional characterization of potential targets with multi-omics data and clinical information to identify targetable vulnerabilities in pediatric sarcomas.

The team Innovative Therapies (S. Ohmura) investigates potential therapeutic targets for pediatric sarcomas through comprehensive analyses crossing omics and clinical data sets. Our scope lies in developing targeted approaches with a particular emphasis on therapy-refractory tumors, which may enable more effective therapies with less adverse effects.


  • Prof. Dr. Dr. Thomas Grünewald (Division Head & Team Leader)
  • Dr. Florencia Cidre-Aranaz (Deputy Division Head & Team Leader)
  • Dr. Shunya Ohmura (Team Leader & Postdoc)
  • Dr. Jing Li (PostDoc)
  • Julian Musa (Physician Scientist)
  • Ji-Young Kim (Physician Scientist)
  • Veronika Bursic (PhD/MD Thesis Student)
  • Martha Julia Carreño Gonzalez (PhD/MD Thesis Student)
  • Katharina Ceranski (PhD/MD Thesis Student)
  • Anna Ehlers (PhD/MD Thesis Student)
  • Tobias Faehling (PhD/MD Thesis Student)
  • Cornelius Funk (PhD/MD Thesis Student)
  • Florian Geyer (PhD/MD Thesis Student)
  • Jia Xiang Jin (PhD/MD Thesis Student)
  • Zuzanna Kolodynska (PhD/MD Thesis Student)
  • David Obermeier (PhD/MD Thesis Student)
  • Carolina Pires (Visiting PhD/MD Thesis Student)
  • Alina Ritter (PhD/MD Thesis Student)
  • Endrit Vinca (PhD/MD Thesis Student)
  • Malenka Zimmermann (PhD/MD Thesis Student)
  • Stefanie Kutschmann (Technician)
  • Felina Zahnow (Technician)
  • Gabriele Meyer (Administration)

More information about the team can be found on the DKFZ website.

Prof. Dr. Dr. Thomas Grünewald

Head of Division "Translational Pediatric Sarcoma Research"

Postal address:

Deutsches Krebsforschungszentrum (DKFZ)
Div. Translational Pediatric Sarcoma Research/B410
Im Neuenheimer Feld 280
69120 Heidelberg



Selected Publications

  1. Cidre-Aranaz F, Li J, Hölting TLB, Orth MF, Imle R, Kutschmann S, Ammirati G, Ceranski K, Carreño-Gonzalez MJ, Kasan M, Marchetto A, Funk CM, Bestvater F, Bersini S, Arrigoni C, Moretti M, Thiel U, Baumhoer D, Sahm F, Pfister SM, Hartmann W, Dirksen U, Romero-Pérez L, Banito A, Ohmura S, Musa J, Kirchner T, Knott MML, Grünewald TG. Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma. Molecular Cancer. 2022 Jan 3;21(1):1
  2. Li J, Ohmura S, Marchetto A, Orth MF, Imle R, Dallmayer M, Musa J, Knott MML, Hölting TLB, Stein S, Funk CM, Sastre A, Alonso J, Bestvater F, Kasan M, Romero-Pérez L, Hartmann W, Ranft A, Banito A, Dirksen U, Kirchner T, Cidre-Aranaz F, Grünewald TGP. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. Nat Commun 2021 Sep 16;12(1):5356
  3. Ohmura S, Marchetto A, Orth MF, Li J, Jabar S, Ranft A, Vinca E, Ceranski K, Carreño-Gonzalez MJ, Romero-Pérez L, Wehweck FS, Musa J, Bestvater F, Knott MML, Hölting TLB, Hartmann W, Dirksen U, Kirchner T, Cidre-Aranaz F, Grünewald TGP. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021 Jul;20(1):97
  4. Marchetto A, Ohmura S, Orth MF, Knott MML, Colombo MV, Arrigoni C, Bardinet V, Saucier D, Wehweck FS, Li J, Stein S, Gerke JS, Baldauf MC, Musa J, Dallmayer M, Romero-Pérez L, Hölting TLB, Amatruda JF, Cossarizza A, Henssen AG, Kirchner T, Moretti M, Cidre-Aranaz F, Sannino G, Grünewald TG. Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. Nat Commun 2020 May;11(1):2423
  5. Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O, Mazor G, Varon M, Hölting TLB, Grossetête S, Gartlgruber M, Surdez D, Gerke JS, Ohmura S, Marchetto A, Dallmayer M, Baldauf MC, Stein S, Sannino G, Li J, Romero-Pérez L, Westermann F, Hartmann W, Dirksen U, Gymrek M, Anderson ND, Shlien A, Rotblat B, Kirchner T, Delattre O, Grünewald TGP. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nat Commun. 2019 Sep;10(1):4128

Awards, Prizes, Scholarships

  • Florian Geyer receives a scholarship as part of the Mildred Scheel doctoral program of the German Cancer Aid.
  • Anna Ehlers receives a scholarship as part of the Mildred Scheel doctoral program of the German Cancer Aid.
  • Tobias Faehling receives a Heinrich F.C. Behr scholarship from the DKFZ and Medical Faculty of the University of Heidelberg.
  • Malenka Zimmermann receives a PhD scholarship of the Kind-Philipp-Stiftung.
  • Thomas Grünewald receives the Rudolf-Virchow-Prize 2020. Press Release (in German only)
  • Cornelius Funk receives a scholarship as part of the Mildred Scheel doctoral program of the German Cancer Aid.
  • Endrit Vinca receives a Heinrich F. C. Behr scholarship from the DKFZ and Medical Faculty of the University of Heidelberg.